IRIS UniCatt

Marchetti, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.302
NA - Nord America 3.726
EU - Europa 2.546
SA - Sud America 1.028
AF - Africa 124
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.737
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.581
SG - Singapore 2.323
BR - Brasile 856
CN - Cina 611
SE - Svezia 590
IT - Italia 568
VN - Vietnam 385
FR - Francia 300
IE - Irlanda 295
DE - Germania 250
IN - India 203
ID - Indonesia 177
HK - Hong Kong 130
GB - Regno Unito 108
JP - Giappone 101
RU - Federazione Russa 84
FI - Finlandia 83
AR - Argentina 79
BD - Bangladesh 64
MX - Messico 63
CZ - Repubblica Ceca 61
CA - Canada 53
IQ - Iraq 53
NL - Olanda 46
TR - Turchia 36
KR - Corea 33
PK - Pakistan 29
AT - Austria 26
CO - Colombia 24
PL - Polonia 24
SA - Arabia Saudita 23
VE - Venezuela 23
ZA - Sudafrica 23
UA - Ucraina 22
BE - Belgio 19
ES - Italia 17
CI - Costa d'Avorio 16
KE - Kenya 15
MA - Marocco 15
TN - Tunisia 15
CH - Svizzera 14
PH - Filippine 14
AZ - Azerbaigian 13
UZ - Uzbekistan 13
EC - Ecuador 12
EG - Egitto 12
NP - Nepal 11
ET - Etiopia 10
IR - Iran 9
JO - Giordania 9
MY - Malesia 9
CL - Cile 8
IL - Israele 8
PY - Paraguay 8
UY - Uruguay 8
BG - Bulgaria 7
KZ - Kazakistan 7
CR - Costa Rica 6
LT - Lituania 6
OM - Oman 6
PE - Perù 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
DZ - Algeria 5
JM - Giamaica 5
TT - Trinidad e Tobago 5
KG - Kirghizistan 4
KW - Kuwait 4
RO - Romania 4
SN - Senegal 4
SY - Repubblica araba siriana 4
AO - Angola 3
HN - Honduras 3
HU - Ungheria 3
LB - Libano 3
PA - Panama 3
PT - Portogallo 3
TJ - Tagikistan 3
AL - Albania 2
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
GY - Guiana 2
LV - Lettonia 2
NG - Nigeria 2
PS - Palestinian Territory 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
Totale 11.721
Salva come PNG Salva come JPEG
Città #
Singapore 1.085
Ashburn 693
San Jose 536
Dublin 291
Chandler 256
Jakarta 167
Lauterbourg 159
Rome 159
Beijing 151
Milan 146
Los Angeles 137
Ho Chi Minh City 131
Boston 124
Hong Kong 119
New York 118
Princeton 116
Hyderabad 103
Hanoi 102
Frankfurt am Main 93
Tokyo 92
Hefei 86
São Paulo 70
Munich 61
Chicago 57
Moscow 57
Helsinki 54
Dallas 53
Washington 53
Santa Clara 49
The Dalles 47
Paris 41
Brno 38
San Mateo 37
Buffalo 35
Orem 32
Seoul 31
Rio de Janeiro 29
Kent 25
Da Nang 24
Nuremberg 24
Amsterdam 23
Council Bluffs 23
London 22
San Francisco 22
Seattle 22
Marseille 20
Atlanta 19
Shanghai 19
Wilmington 19
Chennai 18
Toronto 18
Belo Horizonte 17
Naples 17
Pune 17
Stockholm 17
Vienna 17
Abidjan 16
Baghdad 16
Brussels 16
Denver 16
Houston 16
Warsaw 16
Ann Arbor 15
Brasília 15
Brooklyn 15
Salt Lake City 15
Boardman 14
Bremen 14
Dhaka 14
Mexico City 14
Turku 14
Bari 13
Bogotá 13
Campinas 13
Curitiba 13
Düsseldorf 13
Haiphong 13
Johannesburg 13
Nairobi 13
Poplar 13
Montreal 12
St Louis 12
Tashkent 12
Baku 11
Brdo 11
Porto Alegre 11
Addis Ababa 10
Hải Dương 10
Lappeenranta 10
Manchester 10
Nanjing 10
Olomouc 10
Phoenix 10
Praia Grande 10
Salvador 10
Ankara 9
Contagem 9
Amman 8
Augusta 8
Elk Grove Village 8
Totale 6.535
Salva come PNG Salva come JPEG
Nome #
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study 209
Molecular profile of brca-negative long survivor high grade serous ovarian cancer patients using a somatic multigene panel 163
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments 157
Ovarian reserve after chemotherapy in breast cancer: A systematic review and meta-analysis 147
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance 146
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival? 137
Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach 135
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 132
BRCA testing on buccal swab to improve access to healthcare and cancer prevention: A performance evaluation 124
BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score 123
Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850) 122
Diet and Chemotherapy: The Effects of Fasting and Ketogenic Diet on Cancer Treatment 122
Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation 122
Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients 121
What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study 120
Tolerability of bevacizumab in elderly ovarian cancer patients (Turbo study): A case-control study of a real-life experience 120
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 113
Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study 112
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 112
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence 108
Fertility preservation in patients with BRCA mutations or Lynch syndrome 107
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. 106
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study 106
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer 105
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 103
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients 103
High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment 102
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1 102
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 99
Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era—Is it time for a new paradigm shift? A systematic review and meta-analysis 97
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 96
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer 95
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 94
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study 94
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 92
Letrozole in the management of advanced ovarian cancer: An old drug as a new targeted therapy 92
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery 92
Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact 90
Pembrolizumab for advanced cervical cancer: safety and efficacy 89
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis 89
Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer 89
Value of frozen section to tailor surgical staging in apparent early-stage epithelial ovarian cancer 86
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 86
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status 83
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond 83
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer 82
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 82
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer 80
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 80
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study 80
Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic 77
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 77
Targeted drug delivery via folate receptors in recurrent ovarian cancer: A review 77
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 77
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 76
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 74
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies 73
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes 72
A commentary on the discrepancy between blood and tumour BRCA testing: An open question 71
Fertility preservation in gynaecologic cancers 71
Vulvo-vaginal reconstruction after radical excision for treatment of vulvar cancer: Evaluation of feasibility and morbidity of different surgical techniques 70
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients 69
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 69
Beyond the beyond: First case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: Case report 67
The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis 65
Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing 64
Midtrimester isolated short femur and perinatal outcomes: A systematic review and meta-analysis 64
Ixabepilone for the treatment of endometrial cancer 64
Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis 63
Update on fertility-sparing treatment in primary and recurrent endometrial cancer 63
Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study 62
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors 62
Dualistic classification of epithelial ovarian cancer: Surgical and survival outcomes in a large retrospective series 62
Radiation effects on male fertility 61
Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation 60
Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations 60
Bartholin gland cancer 60
Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling 60
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors 59
Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: Case report and literature review 59
Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role? 58
Threatened abortion and late-pregnancy complications: A case-control study and review of literature 58
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression 58
Nonabsorbable suture granuloma mimicking ovarian cancer recurrence at combined positron emission tomography/computed tomography evaluation: A case report 58
Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence 57
The INCH trial - Induction chemotherapy in patients with bulky anal canal cancer: Evaluation of the pilot phase 57
Vulvodynia: Current opinion and treatment strategies 57
First-line treatment of women with advanced ovarian cancer: Focus on bevacizumab 57
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review 57
Perivascular epithelioid cell neoplasm (PEComa) of the uterus: A systematic review 57
Secondary cytoreductive surgery: Surgical approach to bulky aortic nodes, splenic metastases and mesenteric disease 56
Immune check-point in endometrial cancer 56
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms 55
Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis 55
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials 55
Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis 55
Cediranib in ovarian cancer: state of the art and future perspectives 55
Response to: Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers 54
Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know 54
Late aortic lymphocele and residual ovary syndrome after gynecological surgery 54
Totale 8.560
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.514
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.514
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202124 0 0 0 0 0 0 0 0 0 9 15 0
2021/2022480 17 3 3 23 5 8 14 46 11 27 146 177
2022/20231.358 200 190 113 97 84 192 90 93 148 37 73 41
2023/20241.582 35 337 77 203 87 258 134 43 24 66 172 146
2024/20252.634 61 53 223 74 149 91 74 83 483 328 540 475
2025/20265.791 1.089 154 368 659 1.000 358 1.145 312 401 305 0 0
Totale 12.000